We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00653419
First Posted: April 4, 2008
Last Update Posted: April 4, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Phoenix International Life Sciences, Inc.
Information provided by:
Par Pharmaceutical, Inc.
April 1, 2008
April 4, 2008
April 4, 2008
June 1998
September 1998   (Final data collection date for primary outcome measure)
Rate and extent of absorption [ Time Frame: 24 hours ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions
Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Par and Bristol-Myers Squibb (Buspar) 15 mg Buspirone HCl Tablets in Healthy Adult Males Under Fasting Conditions Following Administration of a 30 mg Dose
To compare the single-dose bioavailability of Par and Bristol-Myers Squibb Buspirone HCl Tablets
To compare the single-dose bioavailability of Par and Bristol-Myers Squibb (Buspar) 15 mg Buspirone HCl Tablets under fasting conditions, following administration of a 30 mg dose
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
To Determine Bioequivalence Under Fasting Conditions
  • Drug: buspirone HCl
    Tablets, 30 mg, single-dose
    Other Name: Buspar
  • Drug: Buspar
    Tablets, 30 mg, single-dose
    Other Name: buspirone HCl
  • Experimental: A
    Subjects received the Par formulated product (Buspirone HCl) under fasting conditions
    Intervention: Drug: buspirone HCl
  • Active Comparator: B
    Subjects received the Bristol-Myers Squibb formulated product (Buspar) under fasting conditions
    Intervention: Drug: Buspar
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
48
September 1998
September 1998   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male volunteers, 18-45 years of age
  • Weighing at least 60 kg, who are within 10% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1983)
  • Physical examination and laboratory tests of hematologic, hepatic and renal functions
  • Medically healthy subjects with clinically normal laboratory profiles will be enrolled in the study

Exclusion Criteria:

  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease
  • The presence of alcoholism or drug abuse within the past year
  • Hypersensitivity or idiosyncratic reaction to buspirone HCl
  • Subjects who have been receiving monoamine oxidase inhibitors
  • Subjects who have been on an abnormal diet (for whatever reason) during the 28 days preceding the study
  • Subjects who, through completion of the study, would have donated in excess of 500 mL blood in 14 days, or 500-750 mL of blood in 14 days (unless approved by Principal Investigator, 1000 mL blood in 90 days, 1250 mL blood in 120 days, 1500 mL blood in 180 days, 2000 mL blood in 270 days, 2500 mL blood in 1 year
  • Subjects who have participated in another clinical trial within 28 days of study start
Sexes Eligible for Study: Male
18 Years to 45 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00653419
980563
No
Not Provided
Not Provided
Alfred Elvin/Director of Biopharmaceutics, Par Pharmaceutical Inc.
Par Pharmaceutical, Inc.
Phoenix International Life Sciences, Inc.
Principal Investigator: Samuel Serfaty, MD Phoenix International Life Sciences, Inc.
Par Pharmaceutical, Inc.
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP